TNFα-blocking agents or conventional immuno-suppressive drugs in the therapy of children with uveitis? - An evidence based approach

Klinische Padiatrie

Volumn 220, Issue 6, 2008, Pages 342-347

  Winterhalter, Sibylle ^a   Niehues, T ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HELIOS Clinic Krefeld   (Germany)

Author keywords

Adalimumab; Etanercept; Evidence based medicine; Immunosuppression; Infliximab; Juvenile idiopathic arthritis; Methotrexate; TNF blocking agents; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA; BONE MARROW DEPRESSION; BURNING SENSATION; CHILD; CHILD HEALTH CARE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEART FAILURE; HIRSUTISM; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INJECTION SITE REACTION; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LIVER TOXICITY; MEDLINE; MONOTHERAPY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PARESTHESIA; RECURRENT INFECTION; RESPIRATORY TRACT DISEASE; RETINA DETACHMENT; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UVEITIS; VASCULITIS; VITREOUS HEMORRHAGE; ARTICLE; DRUG ANTAGONISM; IMMUNOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 56349101077     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1086031     Document Type: Review

References (47)

1. Becker MD, Smith JR, Max Ret al. Management of sight-threating uveitis: new therapeutic options. Drugs 2005; 65: 497-519
2. Beritez-Del-Castillo JM, Carcia-Sanchez J, Iradier T et al. Sulfasalzine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000; 14 (Pt3A): 340-343
3. Biester S, Deuter C, Michels H et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91: 319-324
4. Boer J de, Wulffraat N, Rothova A. Visual loss in uveitis in childhood. Br J Ophthalmol 2003; 87: 879-884
5. Doycheva DG, Deuter C, Stuebiger N et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007; 91: 180-184
6. Edelsten C, Reddy MA, Stanford MR et al. Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 2003; 135: 676-680
7. Feldmann W. Evidence-based Pediatrics, 1 ed. Hamilton: B. Decker; 2000
8. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362-365
9. Foeldvari I, Nielsen S, Kümmerle-Deschner J. Tumor necrosis factor-alpha blocker in the treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 634: 1146-1150
10. Galor A, Jabs DA, Leder HA et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmol 2008, Epub ahead of print
11. Gerloni V, Cimaz R, Gattinara M et al. Efficacy and safety profile of Cyclosprine A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology 2001; 40: 907-913
12. Giannini EH, Brewer EJ, Kuzmina N et al. Result of the USA - UDSSR double-blind, placebo-controlled trial. N Engl J Med 1992; 326: 1043-1049
13. Guignard S, Gossec L, Salliot C et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006; 65: 1631-1634
14. Heiligenhaus A, Mingels A, Heinz C et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti inflammatory medication. Eur J Ophthalmol 2007; 17: 743-748
15. Heiligenhaus A, Horneff G, Greiner K et al. Inhibitors of tumor necrois factor alpha for the treatment of arthritis and uveitis in childhood. Klin Monatsbl Augenheilkd 2007; 224: 526-531
16. Hemady RK, Baer JC, Foster CS. Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 1992; 32: 241-252
17. Kaiplainen-Seppänen O, Leino M. Recurrent uveitis in a patient with juvenile spondylarthropathy associated with tumor necrosis factor inhibitors. Ann Rheum Dis 2003; 62: 88-89
18. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporine A therapy in refracotry noninfectious childhood uveitis. Br J Ophthalmol 1998; 82: 737-742
19. Kotaniemi K. Late onset uveitis in juvenile-type chronic polyarthritis controlled with prednisolone, cyclosporine A and methotrexate. Clin Exp Rheumatol 1998; 16: 549-571
20. Kvien TK, Hoyerall HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 1986; 13: 118-123
21. Lau CH, Comer M, Lightman S. Long-term efficacy of mycophonolate mofetil in the control of severe intaocular inflammation. Clin Experiment Ophthalmol 2003; 31: 487-491
22. Lazar M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969; 67: 383-387
23. Lovell DJ, Giannini EH, Reiff A et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheujmatoid arthritis: interim results from an ongoing multicenter, open-labe, extended-treatment trial. Arthritis Rheum 2003; 48: 218-226
24. Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006; 54: 1987-1994
25. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496-1504
26. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J et al. Sulfasalzine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003; 30: 1277-1279
27. Rajaraman RT, Kumura Y, Li S et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006; 113: 308-314
28. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2005; 89: 925
29. Reiff A, Takei S, Sadeghi S et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411-1415
30. Richards JC, Tay-Kearney ML, Murray K et al. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 2005; 33: 461-468
31. Ruperto N, Murray KJ, Gerloni V et al, Pediatric rheumatology international trials organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-2201
32. Ruperto N, Lovell DJ, Cuttica R et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096-3106
33. Sackett DL, Rosenberg WM, Gray JA. Evidence based medicine: what it is and what it isn't. BMJ 1996; 13: 71-72
34. Samson CM, Waheed N, Baltatzis S et al. Methotrexate therapy for chronic noninfectious uveits: analyses of a case series of 160 patients. Ophthalmology 2001; 108: 1134-1139
35. Saurenmann RK, Levin AV, Rose JB et al. Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006; 45: 982-989
36. Schlote T, Danecker G, Thiel HF et al. Cyclosporine A in therapy of chronic uveitis in childhood. Ophthalmologe 1996; 93: 745-748
37. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005; 44: 1008-1011
38. Shetty AK, Zganjar BE, Ellis GS Jr et al. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus 1999; 36: 125-129
39. Smith JR, Levinson RD, Holland GN et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252-257
40. Smith JA, Thompson DJ, Whitcup SM et al. A randomized, placebo controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005; 53: 18-23
41. SUN-Working Study Group. Perspectives-standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. J Ophthalmol 2005; 140: 509-516
42. Tappeiner C, Roesel M, Heinz C et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 2008, Epub ahead of print
43. Tynjälä P, Lindahl P, Honkanen V et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548-550
44. Rossum MA van, Fiselier TJ, Franssen MJ, Dutch Juvenile Chronic Arthritis Study Group. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Arthritis Rheum 1998; 41: 808-816
45. Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998; 133: 266-268
46. Wells G, Haguenauer D, Shea B et al. Cyclosporine for rheumatoid arthritis. Cochrane Database Syst Rev 2006; 2: CD001083
47. Woo P, Southwood TR, Prieur AM et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43: 1849-1857